密固达治疗绝经后骨质疏松模型大鼠的观察  

Treatment with Aclasta in postmenopausal osteoporosis rats

作　　者：李炜虹[1] 李煜明[2] 崔维顶[3] 吴斌[2] 

机构地区：[1]南京市市级机关医院妇科,江苏南京210018 [2]南京市市级机关医院骨科,江苏南京210018 [3]南京医科大学第一附属医院骨科,江苏南京210029

出　　处：《现代医学》2010年第4期406-407,共2页Modern Medical Journal

基　　金：南京市2006年医学科技发展项目(ykk06132)

摘　　要：目的:探讨密固达对去势后绝经骨质疏松模型大鼠的治疗作用。方法:建立雌性SD大鼠去势后绝经骨质疏松模型16只,随机分为A、B两组,每组8只,A组大鼠给予密固达治疗,B组大鼠去势手术后未行治疗。另选8只正常雌性大鼠作为空白对照组(C组)。喂养12周后测定大鼠骨密度,同时检测血清中骨钙素、骨保护素和骨保护素配体的水平。结果:与B组比较,A组大鼠的骨密度显著增加(P<0.01),血清中骨钙素含量和骨保护素配体/骨保护素值显著降低(P<0.01)。结论:密固达对去势大鼠的骨质疏松有良好的治疗作用,其作用可能与降低血清中骨钙素含量和骨保护素配体/骨保护素值有关。Objective：To study the treating effect of Aclasta on rat postmenopausal osteoporosis.Methods：Sixteen rats models of postmenopausal osteoporosis were established by removing two ovaries of the rats.They were randomly divided into group A and B,with 8 rats each.The rats in group A were administrated with Aclasta,and the rats in group B were not treated.Eight normal female rats were chosen as the controls（group C）.Bone density,serum osteocalcin,osteprotegerin and osteprotegerin ligand were assessed after 12 weeks.Results：The bone density in group A was significantly higher than that in group B（P 0.01）,while the serum osteocalcin level and the ratio of osteprotegerin ligand/osteprotegerin were significantly decreased in group A（P 0.01）.Conclusion：Application of Aclasta has a good therapeutic effect on rat postmenopausal osteoporosis,which may be related to decreasing serum osteocalcin level and the ratio of osteprotegerin ligand/osteprotegerin.

关 键 词：密固达 骨质疏松 大鼠 

分 类 号：R681.1[医药卫生—骨科学]